Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Gross Margin (2020 - 2026)

Longeveron (LGVN) posted quarterly Gross Margin of 66.33% for Q1 2026, down 585.0% year-over-year from 13.68% in Q1 2025, and down 5.79% quarter-over-quarter from 70.41% in Q4 2025.

Longeveron (LGVN) Gross Margin (2020 - 2026) Analysis & Trends

Longeveron's Gross Margin history runs 7 years deep, the most recent figure standing at 66.33% for Q1 2026.

  • In Q1 2026, Gross Margin fell 585.0% year-over-year to 66.33%; the TTM figure through Mar 2026 stood at 65.13% (down 1716.0% YoY), while the FY2025 annual figure was 66.97%, down 1179.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 66.33%, down from 70.41% in the prior quarter.
  • The five-year high for Gross Margin was 92.0% in Q3 2022, with the low at 45.45% in Q4 2022.
  • The 5-year median for Gross Margin is 60.04% (2024), against an average of 52.53%.
  • The sharpest annual moves came in 2022 and 2024: Gross Margin sank 7847 bps in 2022, then jumped 9107 bps in 2024.
  • Longeveron's Gross Margin stood at 45.45% in 2022, then surged by 93 bps to 3.17% in 2023, then soared by 2869 bps to 87.89% in 2024, then retreated by 20 bps to 70.41% in 2025, then fell by 6 bps to 66.33% in 2026.
  • Business Quant data shows LGVN's Gross Margin at 66.33% in Q1 2026, 70.41% in Q4 2025, and 91.24% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 85.33%
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 91.59%
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 90.43%
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 35.86%
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 89.76%
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 76.90%
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 63.27%
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 84.20%
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 63.41%

Historic Data

Download Data
DateValue
Jun 30, 2026 63.41%
Mar 31, 2026 66.33%
Dec 31, 2025 70.41%
Sep 30, 2025 91.24%
Jun 30, 2025 46.20%
Mar 31, 2025 72.18%
Dec 31, 2024 87.89%
Sep 30, 2024 88.23%
Jun 30, 2024 73.50%
Mar 31, 2024 60.04%
Dec 31, 2023 -3.17%
Sep 30, 2023 36.00%
Jun 30, 2023 42.86%
Mar 31, 2023 27.24%
Dec 31, 2022 -45.45%
Sep 30, 2022 92.00%
Jun 30, 2022 34.33%
Mar 31, 2022 53.23%
Dec 31, 2021 33.01%
Sep 30, 2021 70.69%